-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Waldenstrom Macroglobulinemia Clinical Trial Report Overview A total of 709 Waldenstrom Macroglobulinemia clinical trials were conducted as of December 2023. The Waldenstrom Macroglobulinemia clinical trial report provides a comprehensive understanding of the Waldenstrom Macroglobulinemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Sector Analysis
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Report Overview Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). The subtypes of NHL are defined by the cell of origin, the location involved, and the extensive histopathologic, immunophenotypic, and genetic criteria. B-cell NHLs generally arise in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to distant sites such as the lung or brain in the later...
-
Sector Analysis
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Market Report Overview B-cell NHL generally arises in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to involve distant sites such as the lung or brain in the later stages of the disease. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence outcomes and treatment decisions. The B-Cell NHL marketed, and pipeline drugs market research report includes an assessment of...
-
Sector Analysis
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031
B-Cell Non-Hodgkins Lymphoma Cell Therapy  Market Report Overview The total market value for the 15M, which includes both cell therapies and established/traditional NHL therapies was $16.1 billion in 2021. The market growth will be attributed to the Kymriah, Yescarta, Breyanzi, and Carteyva, which will receive label expansions into earlier lines of therapy and new NHL subtypes. B-Cell Non-Hodgkins Lymphoma Cell Therapy  Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the B-Cell Non-Hodgkins Lymphoma Cell Therapy...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.